Clinical Trials Directory

Trials / Unknown

UnknownNCT02882451

Impact of Pinaverium Bromide on Bile Duct and Pancreatic Duct Cannulation During Endoscopic Retrograde Cholangiopancreatography

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
200 (estimated)
Sponsor
Changhai Hospital · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Accepted

Summary

Pinaverium bromide can be used to treat symptoms related to irritable bowel syndrome (IBS) and functional disorders of the biliary tract. In this study, pinaverium bromide was compared with Vitamin C for the facilitation of bile duct and pancreatic duct cannulation in patients. The primary outcome was successful deep bile duct cannulation and pancreatic duct canulation. The second outcome was the major papillary orifice,bile juice flow from the papilla, time to achieve deep bile duct cannulation, fluoroscopy time for deep bile duct cannulation,the appearance of the major and minor papillary orifice, pancreatic juice flow from the papilla, time to achieve deep pancreatic duct cannulation, and fluoroscopy time for deep pancreatic duct cannulation in the pinaverium bromide group versus Vitamin C group.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTpinaverium bromide
DIETARY_SUPPLEMENTVitamin C

Timeline

Start date
2016-07-01
Primary completion
2017-08-01
Completion
2017-10-01
First posted
2016-08-29
Last updated
2017-06-12

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02882451. Inclusion in this directory is not an endorsement.

Impact of Pinaverium Bromide on Bile Duct and Pancreatic Duct Cannulation During Endoscopic Retrograde Cholangiopancreat (NCT02882451) · Clinical Trials Directory